Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)

Phase 2/3 Terminated 344 enrolled Merck Sharp & Dohme LLC

RandomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of this study is to compare the efficacy of polyethylene glycol (PEG; pegylated) interferon alfa-2b (PEG Intron, C98026) versus interferon alfa-2b (Intron® A) in the treatment of participants with newly diagnosed CML.

Timeline

Start: 1998-10-22
Primary completion: 2001-02-20
Completion: 2001-02-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Peginterferon alfa-2b	Protein / enzyme biologic	6 ug/kg	Subcutaneous
Subject	interferon alfa-2b	Protein / enzyme biologic	5 unknown	Subcutaneous

Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)

Summary

Timeline

Drugs

Indications